Pharmaceutical News

PARIS--(BUSINESS WIRE)--Lorient captured global attention at IMCAS 2026 with expert-led sessions, proving its excellence in safety and the effectiveness of its products....

SHANGHAI--(BUSINESS WIRE)--GAH and Tenacia announce a China commercialization partnership for ZTALMY, the first approved therapy for CDKL5 deficiency disorder....

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--AHF Receives Expedited FL Hearing Opposing ADAP Reductions...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 257,368 shares of common stock. Awards were made to 20 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee...

MILWAUKEE--(BUSINESS WIRE)--Sensient Technologies Corporation (NYSE: SXT) will hold its earnings call and webcast to discuss 2025 fourth quarter and year-end results at 8:30 a.m. CST on Friday, February 13, 2026. Investors may access the live webcast on the Company’s web site at investor.sensient.com. Alternatively, investors may join the conference call by contacting Chorus Call Inc. at (844) 492-3726 or (412) 317-1078. A webcast replay will be available on the Company’s web site following the...

SAN DIEGO--(BUSINESS WIRE)--Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program...

DUBLIN--(BUSINESS WIRE)--The "CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Report Highlights: First CD137 Targeted Therapy Commercial Launch Expected by 2030 Insight on CD137 Targeted Therapies in Clinical Trials: > 90 Therapies CD137 Targeted Therapies Clinical Trials Insight by Company, Country, Indication and Phase Highest Clinical Trials P...

DUBLIN--(BUSINESS WIRE)--The "MYC Targeting Therapies Market Opportunity, Targeting Approaches, Technology Development Platforms & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: First MYC Targeting Therapy Approval Expected by 2030 Global MYC Targeting Therapies Market Opportunity Outlook Comprehensive Insight on MYC Targeting Therapies in Clinical Trials: > 10 Therapies MYC Targeting Drugs Clinical Trials Insig...

DUBLIN--(BUSINESS WIRE)--The "Molecular Switch Targeting Therapies Market Landscape, Innovation Pipeline and Commercial Impact 2026" report has been added to ResearchAndMarkets.com's offering. The report is designed to give stakeholders an overview of the current landscape regarding Molecular Switch Targeting Therapies, offering an understanding of their immense therapeutic potential, ongoing innovations, and key players driving revolution in this space. Report Findings & Highlights: Top 20...

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--In continuing to stand up against the proposed cuts to Florida’s AIDS Drug Assistance Program (ADAP), advocates with AIDS Healthcare Foundation (AHF) will host simultaneous protests at the local department of health offices in Orlando, Florida and St. Petersburg, Florida. Taking place at 10:30am ET on Friday, January 30, 2026, the protests will take place at 205 Dr. Martin Luther King, Jr. Street North, St. Petersburg, FL and 932 W. Central Blvd., Orlando...